Bozigian Haig P. 4

4 · NEUROCRINE BIOSCIENCES INC · Filed May 14, 2020

Form 4

Period: 2020-05-12

Sr Vice President, Development

Transactions

Exercise/Conversion
Common Stock
2020-05-12$35.99/sh+9,094$327,293→ 157,727 total
Sale
Common Stock
2020-05-12$114.94/sh−9,094$1,045,303→ 148,633 total
Exercise/Conversion
Common Stock
2020-05-12$43.24/sh+18,571$803,010→ 167,204 total
Sale
Common Stock
2020-05-12$114.94/sh−18,571$2,134,631→ 148,633 total
Exercise/Conversion
Common Stock
2020-05-12$81.49/sh+15,833$1,290,231→ 164,466 total
Sale
Common Stock
2020-05-12$114.94/sh−15,833$1,819,913→ 148,633 total
Exercise/Conversion
Common Stock
2020-05-12$81.05/sh+18,057$1,463,520→ 166,690 total
Sale
Common Stock
2020-05-12$114.94/sh−18,057$2,075,549→ 148,633 total
Exercise/Conversion
Non-Qualified Stock Option
2020-05-12−9,094→ 0 total
Exercise: $35.99Exp: 2026-02-05→ Common Stock (9,094 underlying)
Exercise/Conversion
Non-Qualified Stock Option
2020-05-12−18,571→ 15,289 total
Exercise: $43.24Exp: 2027-02-06→ Common Stock (18,571 underlying)
Exercise/Conversion
Non-Qualified Stock Option
2020-05-12−15,833→ 13,340 total
Exercise: $81.49Exp: 2028-02-05→ Common Stock (15,833 underlying)
Exercise/Conversion
Non-Qualified Stock Option
2020-05-12−18,057→ 47,383 total
Exercise: $81.05Exp: 2029-02-07→ Common Stock (18,057 underlying)

Footnotes (6)

[F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
[F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.43 to $117.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F3]Option granted February 05, 2016 and vested monthly over four years.
[F4]Option granted February 06, 2017 and vests monthly over four years.
[F5]Option granted February 05, 2018 and vests monthly over four years.
[F6]Option granted February 07, 2019 and vests monthly over four years.

Documents

1 file